Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel Free PRM Stock Alerts

Proteome Sciences (PRM) Competitors

Proteome Sciences logo
GBX 1.72 -0.08 (-4.44%)
As of 08/14/2026 11:32 AM Eastern
Compare

PRM vs. ABDX, GDR, YGEN, AGL, and VRCI

Should you buy Proteome Sciences stock or one of its competitors? Proteome Sciences's main competitors and comparable companies include Abingdon Health (ABDX), genedrive (GDR), Yourgene Health (YGEN), ANGLE (AGL), and Verici Dx (VRCI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Proteome Sciences compare to Abingdon Health?

Abingdon Health (LON:ABDX) and Proteome Sciences (LON:PRM) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, valuation, earnings, analyst recommendations, institutional ownership and profitability.

Abingdon Health has higher revenue and earnings than Proteome Sciences. Abingdon Health is trading at a lower price-to-earnings ratio than Proteome Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abingdon Health£9.57M2.63-£796.37K-£0.81N/A
Proteome Sciences£3.76M1.61-£4.08M-£1.04N/A

Abingdon Health has a beta of 0.16, meaning that its stock price is 84% less volatile than the broader market. Comparatively, Proteome Sciences has a beta of 0.148, meaning that its stock price is 85% less volatile than the broader market.

Abingdon Health has a net margin of -33.88% compared to Proteome Sciences' net margin of -81.50%. Proteome Sciences' return on equity of 33.80% beat Abingdon Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Abingdon Health-33.88% -55.91% -17.93%
Proteome Sciences -81.50%33.80%-19.25%

3.7% of Abingdon Health shares are owned by institutional investors. Comparatively, 0.0% of Proteome Sciences shares are owned by institutional investors. 8.0% of Abingdon Health shares are owned by company insiders. Comparatively, 36.7% of Proteome Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Abingdon Health's average media sentiment score of 0.00 equaled Proteome Sciences'average media sentiment score.

Company Overall Sentiment
Abingdon Health Neutral
Proteome Sciences Neutral

Summary

Abingdon Health beats Proteome Sciences on 8 of the 11 factors compared between the two stocks.

How does Proteome Sciences compare to genedrive?

genedrive (LON:GDR) and Proteome Sciences (LON:PRM) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

Proteome Sciences has higher revenue and earnings than genedrive. Proteome Sciences is trading at a lower price-to-earnings ratio than genedrive, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
genedrive£929K20.17-£21.22M-£0.79N/A
Proteome Sciences£3.76M1.61-£4.08M-£1.04N/A

Proteome Sciences has a net margin of -81.50% compared to genedrive's net margin of -500.75%. Proteome Sciences' return on equity of 33.80% beat genedrive's return on equity.

Company Net Margins Return on Equity Return on Assets
genedrive-500.75% -1,044.57% -74.09%
Proteome Sciences -81.50%33.80%-19.25%

0.1% of genedrive shares are held by institutional investors. Comparatively, 0.0% of Proteome Sciences shares are held by institutional investors. 29.0% of genedrive shares are held by insiders. Comparatively, 36.7% of Proteome Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

genedrive has a beta of 0.989, suggesting that its share price is 1% less volatile than the broader market. Comparatively, Proteome Sciences has a beta of 0.148, suggesting that its share price is 85% less volatile than the broader market.

In the previous week, genedrive had 1 more articles in the media than Proteome Sciences. MarketBeat recorded 1 mentions for genedrive and 0 mentions for Proteome Sciences. genedrive's average media sentiment score of 0.00 equaled Proteome Sciences'average media sentiment score.

Company Overall Sentiment
genedrive Neutral
Proteome Sciences Neutral

Summary

genedrive and Proteome Sciences tied by winning 6 of the 12 factors compared between the two stocks.

How does Proteome Sciences compare to Yourgene Health?

Proteome Sciences (LON:PRM) and Yourgene Health (LON:YGEN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability.

Proteome Sciences has a beta of 0.148, meaning that its share price is 85% less volatile than the broader market. Comparatively, Yourgene Health has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market.

Yourgene Health has a net margin of -27.55% compared to Proteome Sciences' net margin of -81.50%. Proteome Sciences' return on equity of 33.80% beat Yourgene Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Proteome Sciences-81.50% 33.80% -19.25%
Yourgene Health -27.55%-27.06%-6.71%

In the previous week, Proteome Sciences' average media sentiment score of 0.00 equaled Yourgene Health'saverage media sentiment score.

Company Overall Sentiment
Proteome Sciences Neutral
Yourgene Health Neutral

Proteome Sciences has higher earnings, but lower revenue than Yourgene Health. Proteome Sciences is trading at a lower price-to-earnings ratio than Yourgene Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Proteome Sciences£3.76M1.61-£4.08M-£1.04N/A
Yourgene Health£29.67M0.00-£8.17M-£0.01N/A

0.0% of Proteome Sciences shares are held by institutional investors. Comparatively, 23.3% of Yourgene Health shares are held by institutional investors. 36.7% of Proteome Sciences shares are held by company insiders. Comparatively, 64.4% of Yourgene Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Yourgene Health beats Proteome Sciences on 7 of the 10 factors compared between the two stocks.

How does Proteome Sciences compare to ANGLE?

ANGLE (LON:AGL) and Proteome Sciences (LON:PRM) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

ANGLE has a beta of 0.22, meaning that its stock price is 78% less volatile than the broader market. Comparatively, Proteome Sciences has a beta of 0.148, meaning that its stock price is 85% less volatile than the broader market.

17.5% of ANGLE shares are held by institutional investors. Comparatively, 0.0% of Proteome Sciences shares are held by institutional investors. 2.7% of ANGLE shares are held by company insiders. Comparatively, 36.7% of Proteome Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Proteome Sciences has a net margin of -81.50% compared to ANGLE's net margin of -1,444.04%. Proteome Sciences' return on equity of 33.80% beat ANGLE's return on equity.

Company Net Margins Return on Equity Return on Assets
ANGLE-1,444.04% -191.36% -29.89%
Proteome Sciences -81.50%33.80%-19.25%

In the previous week, ANGLE had 1 more articles in the media than Proteome Sciences. MarketBeat recorded 1 mentions for ANGLE and 0 mentions for Proteome Sciences. Proteome Sciences' average media sentiment score of 0.00 beat ANGLE's score of -0.08 indicating that Proteome Sciences is being referred to more favorably in the news media.

Company Overall Sentiment
ANGLE Neutral
Proteome Sciences Neutral

Proteome Sciences has higher revenue and earnings than ANGLE. Proteome Sciences is trading at a lower price-to-earnings ratio than ANGLE, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ANGLE£2.62M2.89-£21.76M-£4.80N/A
Proteome Sciences£3.76M1.61-£4.08M-£1.04N/A

Summary

Proteome Sciences beats ANGLE on 8 of the 13 factors compared between the two stocks.

How does Proteome Sciences compare to Verici Dx?

Proteome Sciences (LON:PRM) and Verici Dx (LON:VRCI) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Proteome Sciences has a net margin of -81.50% compared to Verici Dx's net margin of -193.05%. Proteome Sciences' return on equity of 33.80% beat Verici Dx's return on equity.

Company Net Margins Return on Equity Return on Assets
Proteome Sciences-81.50% 33.80% -19.25%
Verici Dx -193.05%-138.93%-26.14%

In the previous week, Proteome Sciences' average media sentiment score of 0.00 equaled Verici Dx'saverage media sentiment score.

Company Overall Sentiment
Proteome Sciences Neutral
Verici Dx Neutral

Proteome Sciences has a beta of 0.148, suggesting that its stock price is 85% less volatile than the broader market. Comparatively, Verici Dx has a beta of 1.256, suggesting that its stock price is 26% more volatile than the broader market.

0.0% of Proteome Sciences shares are owned by institutional investors. Comparatively, 15.7% of Verici Dx shares are owned by institutional investors. 36.7% of Proteome Sciences shares are owned by insiders. Comparatively, 1.2% of Verici Dx shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Proteome Sciences has higher revenue and earnings than Verici Dx. Proteome Sciences is trading at a lower price-to-earnings ratio than Verici Dx, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Proteome Sciences£3.76M1.61-£4.08M-£1.04N/A
Verici Dx£3.66M1.55-£6.56M-£0.90N/A

Summary

Proteome Sciences beats Verici Dx on 7 of the 11 factors compared between the two stocks.

Get Proteome Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for PRM and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PRM vs. The Competition

Export
MetricProteome SciencesLife Sciences Tools & Services IndustryHealthcare SectorLON Exchange
Market Cap£6.03M£9.56B£7.04B£2.88B
Dividend Yield6.17%1.46%2.57%6.11%
P/E Ratio-1.6549.17214.69368.68
Price / Sales1.61105.71617.3583,339.32
Price / Cash3.7326.1175.7027.89
Price / Book-0.9637.5012.927.18
Net Income-£4.08M£56.66B£3.45B£5.89B
7 Day Performance7.50%0.29%1.16%0.91%
1 Month Performance-14.00%1.38%1.37%2.94%
1 Year Performance-31.75%17.34%62.53%64.32%

Proteome Sciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PRM
Proteome Sciences
N/AGBX 1.72
-4.4%		N/A-44.3%£6.03M£3.76MN/A240
ABDX
Abingdon Health
N/AGBX 10.43
-0.7%		N/A+62.2%£26.18M£9.57MN/A84
GDR
genedrive
N/AGBX 1.19
+3.5%		N/A+37.3%£19.11M£929KN/A43
YGEN
Yourgene Health
N/AN/AN/AN/A£16.43M£29.67MN/A253
AGL
ANGLE
N/AGBX 2.35
-11.3%		N/A-55.7%£7.58M£2.62MN/A650

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:PRM) was last updated on 8/15/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel